NovaBay Pharmaceuticals, Inc.
NBY
$0.60
$0.000.00%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 8.60% | -1.90% | -32.25% | 12.52% |
| Total Other Revenue | -- | 89.29% | 70.00% | 18.18% | 0.00% |
| Total Revenue | -- | 9.90% | -1.61% | -32.09% | 12.48% |
| Cost of Revenue | -- | -20.73% | 3.54% | -54.99% | -- |
| Gross Profit | -- | 38.69% | -4.15% | -8.45% | -- |
| SG&A Expenses | 17.90% | 32.87% | 12.48% | -4.77% | -21.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.90% | 15.73% | 10.16% | -24.69% | -37.81% |
| Operating Income | -17.90% | -27.88% | -52.01% | -0.19% | -70.33% |
| Income Before Tax | -13.85% | 23.04% | 10.42% | 8.28% | -117.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.85% | 23.04% | 10.42% | 8.28% | -117.47% |
| Earnings from Discontinued Operations | 3,906.23% | 104.65% | -- | -- | 26.65% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 338.64% | 70.50% | 31.02% | 22.15% | -84.82% |
| EBIT | -17.90% | -27.88% | -52.01% | -0.19% | -70.33% |
| EBITDA | -18.43% | -28.61% | -53.58% | -0.39% | -71.10% |
| EPS Basic | 104.82% | 99.67% | 95.44% | 96.90% | -0.14% |
| Normalized Basic EPS | 97.93% | 98.10% | 96.80% | 93.31% | -7.71% |
| EPS Diluted | 104.82% | 99.67% | 95.44% | 96.90% | -0.14% |
| Normalized Diluted EPS | 97.97% | 98.10% | 96.80% | 93.31% | -7.71% |
| Average Basic Shares Outstanding | 4,323.33% | 3,956.32% | 2,668.66% | 1,169.23% | 106.54% |
| Average Diluted Shares Outstanding | 4,412.50% | 3,956.32% | 2,668.66% | 1,169.23% | 106.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |